JP2019500869A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019500869A5 JP2019500869A5 JP2018529087A JP2018529087A JP2019500869A5 JP 2019500869 A5 JP2019500869 A5 JP 2019500869A5 JP 2018529087 A JP2018529087 A JP 2018529087A JP 2018529087 A JP2018529087 A JP 2018529087A JP 2019500869 A5 JP2019500869 A5 JP 2019500869A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- antibody
- molar ratio
- composition
- motomeko
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims description 49
- 102100035360 Cerebellar degeneration-related antigen 1 Human genes 0.000 claims description 41
- 239000000427 antigen Substances 0.000 claims description 29
- 102000036639 antigens Human genes 0.000 claims description 29
- 108091007433 antigens Proteins 0.000 claims description 29
- 230000035772 mutation Effects 0.000 claims description 29
- 101000610604 Homo sapiens Tumor necrosis factor receptor superfamily member 10B Proteins 0.000 claims description 21
- 238000006467 substitution reaction Methods 0.000 claims description 17
- 102000053594 human TNFRSF10B Human genes 0.000 claims description 15
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 14
- 206010028980 Neoplasm Diseases 0.000 claims description 13
- 125000000539 amino acid group Chemical group 0.000 claims description 12
- 230000006907 apoptotic process Effects 0.000 claims description 8
- 201000011510 cancer Diseases 0.000 claims description 7
- 239000003814 drug Substances 0.000 claims description 7
- 230000030833 cell death Effects 0.000 claims description 6
- 102000039446 nucleic acids Human genes 0.000 claims description 5
- 150000007523 nucleic acids Chemical class 0.000 claims description 5
- 108020004707 nucleic acids Proteins 0.000 claims description 5
- 206010009944 Colon cancer Diseases 0.000 claims description 4
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 4
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims description 4
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims description 4
- 239000002246 antineoplastic agent Substances 0.000 claims description 4
- 239000013604 expression vector Substances 0.000 claims description 4
- 201000005787 hematologic cancer Diseases 0.000 claims description 4
- 239000008194 pharmaceutical composition Substances 0.000 claims description 4
- 201000000849 skin cancer Diseases 0.000 claims description 4
- 229940124597 therapeutic agent Drugs 0.000 claims description 4
- 102000011727 Caspases Human genes 0.000 claims description 3
- 108010076667 Caspases Proteins 0.000 claims description 3
- 239000007787 solid Substances 0.000 claims description 3
- 108010013043 Acetylesterase Proteins 0.000 claims description 2
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims description 2
- 206010052747 Adenocarcinoma pancreas Diseases 0.000 claims description 2
- 206010003571 Astrocytoma Diseases 0.000 claims description 2
- 208000023275 Autoimmune disease Diseases 0.000 claims description 2
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims description 2
- MLDQJTXFUGDVEO-UHFFFAOYSA-N BAY-43-9006 Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=CC(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 MLDQJTXFUGDVEO-UHFFFAOYSA-N 0.000 claims description 2
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims description 2
- 206010005003 Bladder cancer Diseases 0.000 claims description 2
- 206010006187 Breast cancer Diseases 0.000 claims description 2
- 208000026310 Breast neoplasm Diseases 0.000 claims description 2
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 2
- 208000005243 Chondrosarcoma Diseases 0.000 claims description 2
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims description 2
- 206010052360 Colorectal adenocarcinoma Diseases 0.000 claims description 2
- 208000035473 Communicable disease Diseases 0.000 claims description 2
- 108090000695 Cytokines Proteins 0.000 claims description 2
- 102000004127 Cytokines Human genes 0.000 claims description 2
- 206010014733 Endometrial cancer Diseases 0.000 claims description 2
- 206010014759 Endometrial neoplasm Diseases 0.000 claims description 2
- HKVAMNSJSFKALM-GKUWKFKPSA-N Everolimus Chemical compound C1C[C@@H](OCCO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 HKVAMNSJSFKALM-GKUWKFKPSA-N 0.000 claims description 2
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 claims description 2
- 102000006947 Histones Human genes 0.000 claims description 2
- 108010033040 Histones Proteins 0.000 claims description 2
- 208000017604 Hodgkin disease Diseases 0.000 claims description 2
- 208000021519 Hodgkin lymphoma Diseases 0.000 claims description 2
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims description 2
- 101000830565 Homo sapiens Tumor necrosis factor ligand superfamily member 10 Proteins 0.000 claims description 2
- 108060003951 Immunoglobulin Proteins 0.000 claims description 2
- 102100037850 Interferon gamma Human genes 0.000 claims description 2
- 108010074328 Interferon-gamma Proteins 0.000 claims description 2
- 239000002147 L01XE04 - Sunitinib Substances 0.000 claims description 2
- 239000005511 L01XE05 - Sorafenib Substances 0.000 claims description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 2
- 206010025323 Lymphomas Diseases 0.000 claims description 2
- 208000034578 Multiple myelomas Diseases 0.000 claims description 2
- 201000003793 Myelodysplastic syndrome Diseases 0.000 claims description 2
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims description 2
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims description 2
- 206010029260 Neuroblastoma Diseases 0.000 claims description 2
- 206010052399 Neuroendocrine tumour Diseases 0.000 claims description 2
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims description 2
- 206010033128 Ovarian cancer Diseases 0.000 claims description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 2
- 229930012538 Paclitaxel Natural products 0.000 claims description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 2
- 239000001825 Polyoxyethene (8) stearate Substances 0.000 claims description 2
- 229940079156 Proteasome inhibitor Drugs 0.000 claims description 2
- 229940078123 Ras inhibitor Drugs 0.000 claims description 2
- 208000000453 Skin Neoplasms Diseases 0.000 claims description 2
- 206010041067 Small cell lung cancer Diseases 0.000 claims description 2
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 2
- BPEGJWRSRHCHSN-UHFFFAOYSA-N Temozolomide Chemical compound O=C1N(C)N=NC2=C(C(N)=O)N=CN21 BPEGJWRSRHCHSN-UHFFFAOYSA-N 0.000 claims description 2
- 208000003721 Triple Negative Breast Neoplasms Diseases 0.000 claims description 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 2
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims description 2
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims description 2
- 239000000556 agonist Substances 0.000 claims description 2
- 239000000611 antibody drug conjugate Substances 0.000 claims description 2
- 229940049595 antibody-drug conjugate Drugs 0.000 claims description 2
- 238000003782 apoptosis assay Methods 0.000 claims description 2
- 229940076005 apoptosis modulator Drugs 0.000 claims description 2
- 229960001467 bortezomib Drugs 0.000 claims description 2
- GXJABQQUPOEUTA-RDJZCZTQSA-N bortezomib Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)B(O)O)NC(=O)C=1N=CC=NC=1)C1=CC=CC=C1 GXJABQQUPOEUTA-RDJZCZTQSA-N 0.000 claims description 2
- 229960004562 carboplatin Drugs 0.000 claims description 2
- 190000008236 carboplatin Chemical compound 0.000 claims description 2
- 201000007455 central nervous system cancer Diseases 0.000 claims description 2
- 201000010881 cervical cancer Diseases 0.000 claims description 2
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims description 2
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims description 2
- 229960004316 cisplatin Drugs 0.000 claims description 2
- 201000010989 colorectal carcinoma Diseases 0.000 claims description 2
- 229940127089 cytotoxic agent Drugs 0.000 claims description 2
- 230000001419 dependent effect Effects 0.000 claims description 2
- 235000015872 dietary supplement Nutrition 0.000 claims description 2
- 229960004679 doxorubicin Drugs 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 230000002526 effect on cardiovascular system Effects 0.000 claims description 2
- 229960005167 everolimus Drugs 0.000 claims description 2
- 229960002949 fluorouracil Drugs 0.000 claims description 2
- 201000006585 gastric adenocarcinoma Diseases 0.000 claims description 2
- 206010017758 gastric cancer Diseases 0.000 claims description 2
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 claims description 2
- 229960005277 gemcitabine Drugs 0.000 claims description 2
- 208000005017 glioblastoma Diseases 0.000 claims description 2
- 208000014829 head and neck neoplasm Diseases 0.000 claims description 2
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 claims description 2
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims description 2
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims description 2
- 102000044949 human TNFSF10 Human genes 0.000 claims description 2
- 102000018358 immunoglobulin Human genes 0.000 claims description 2
- 208000015181 infectious disease Diseases 0.000 claims description 2
- 239000003112 inhibitor Substances 0.000 claims description 2
- 229960004768 irinotecan Drugs 0.000 claims description 2
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 claims description 2
- 229940043355 kinase inhibitor Drugs 0.000 claims description 2
- 201000005202 lung cancer Diseases 0.000 claims description 2
- 208000020816 lung neoplasm Diseases 0.000 claims description 2
- 239000004337 magnesium citrate Substances 0.000 claims description 2
- 230000036244 malformation Effects 0.000 claims description 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 2
- 201000009020 malignant peripheral nerve sheath tumor Diseases 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 208000025113 myeloid leukemia Diseases 0.000 claims description 2
- 208000016065 neuroendocrine neoplasm Diseases 0.000 claims description 2
- 201000011519 neuroendocrine tumor Diseases 0.000 claims description 2
- 208000029974 neurofibrosarcoma Diseases 0.000 claims description 2
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims description 2
- 201000008968 osteosarcoma Diseases 0.000 claims description 2
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 claims description 2
- 229960001756 oxaliplatin Drugs 0.000 claims description 2
- 229960001592 paclitaxel Drugs 0.000 claims description 2
- 201000002094 pancreatic adenocarcinoma Diseases 0.000 claims description 2
- 201000002528 pancreatic cancer Diseases 0.000 claims description 2
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 2
- 229960005079 pemetrexed Drugs 0.000 claims description 2
- QOFFJEBXNKRSPX-ZDUSSCGKSA-N pemetrexed Chemical compound C1=N[C]2NC(N)=NC(=O)C2=C1CCC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 QOFFJEBXNKRSPX-ZDUSSCGKSA-N 0.000 claims description 2
- 239000003757 phosphotransferase inhibitor Substances 0.000 claims description 2
- 230000005522 programmed cell death Effects 0.000 claims description 2
- 239000003207 proteasome inhibitor Substances 0.000 claims description 2
- 201000008261 skin carcinoma Diseases 0.000 claims description 2
- 229960003787 sorafenib Drugs 0.000 claims description 2
- 201000011549 stomach cancer Diseases 0.000 claims description 2
- 229960001796 sunitinib Drugs 0.000 claims description 2
- WINHZLLDWRZWRT-ATVHPVEESA-N sunitinib Chemical compound CCN(CC)CCNC(=O)C1=C(C)NC(\C=C/2C3=CC(F)=CC=C3NC\2=O)=C1C WINHZLLDWRZWRT-ATVHPVEESA-N 0.000 claims description 2
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims description 2
- 229960004964 temozolomide Drugs 0.000 claims description 2
- 238000002560 therapeutic procedure Methods 0.000 claims description 2
- 208000022679 triple-negative breast carcinoma Diseases 0.000 claims description 2
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 2
- WAEXFXRVDQXREF-UHFFFAOYSA-N vorinostat Chemical compound ONC(=O)CCCCCCC(=O)NC1=CC=CC=C1 WAEXFXRVDQXREF-UHFFFAOYSA-N 0.000 claims description 2
- 229960000237 vorinostat Drugs 0.000 claims description 2
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- 206010039491 Sarcoma Diseases 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- 210000004185 liver Anatomy 0.000 claims 1
- 208000026037 malignant tumor of neck Diseases 0.000 claims 1
- 201000008129 pancreatic ductal adenocarcinoma Diseases 0.000 claims 1
- 210000004027 cell Anatomy 0.000 description 9
- 238000000034 method Methods 0.000 description 3
- 102000003952 Caspase 3 Human genes 0.000 description 2
- 108090000397 Caspase 3 Proteins 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 230000035899 viability Effects 0.000 description 2
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 description 1
- 102000004041 Caspase 7 Human genes 0.000 description 1
- 108090000567 Caspase 7 Proteins 0.000 description 1
- 229940123169 Caspase inhibitor Drugs 0.000 description 1
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 description 1
- 206010055006 Pancreatic sarcoma Diseases 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 201000010536 head and neck cancer Diseases 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 201000002526 pancreas sarcoma Diseases 0.000 description 1
- 210000001236 prokaryotic cell Anatomy 0.000 description 1
Applications Claiming Priority (11)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DKPA201500771 | 2015-12-01 | ||
| DKPA201500771 | 2015-12-01 | ||
| DKPA201500788 | 2015-12-07 | ||
| DKPA201500788 | 2015-12-07 | ||
| DKPA201500787 | 2015-12-07 | ||
| DKPA201500787 | 2015-12-07 | ||
| DKPA201600701 | 2016-11-10 | ||
| DKPA201600702 | 2016-11-10 | ||
| DKPA201600701 | 2016-11-10 | ||
| DKPA201600702 | 2016-11-10 | ||
| PCT/EP2016/079518 WO2017093448A1 (en) | 2015-12-01 | 2016-12-01 | Anti-dr5 antibodies and methods of use thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019500869A JP2019500869A (ja) | 2019-01-17 |
| JP2019500869A5 true JP2019500869A5 (OSRAM) | 2020-01-16 |
| JP7254515B2 JP7254515B2 (ja) | 2023-04-10 |
Family
ID=58796495
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018529176A Withdrawn JP2019501151A (ja) | 2015-12-01 | 2016-12-01 | 抗デスレセプター抗体およびその使用方法 |
| JP2018529087A Active JP7254515B2 (ja) | 2015-12-01 | 2016-12-01 | 抗ｄｒ５抗体およびその使用方法 |
| JP2022188988A Active JP7679347B2 (ja) | 2015-12-01 | 2022-11-28 | 抗デスレセプター抗体およびその使用方法 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018529176A Withdrawn JP2019501151A (ja) | 2015-12-01 | 2016-12-01 | 抗デスレセプター抗体およびその使用方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022188988A Active JP7679347B2 (ja) | 2015-12-01 | 2022-11-28 | 抗デスレセプター抗体およびその使用方法 |
Country Status (15)
| Country | Link |
|---|---|
| US (5) | US20190144554A1 (OSRAM) |
| EP (4) | EP3383906A1 (OSRAM) |
| JP (3) | JP2019501151A (OSRAM) |
| KR (1) | KR20180098567A (OSRAM) |
| CN (2) | CN109476737A (OSRAM) |
| AU (2) | AU2016363770A1 (OSRAM) |
| BR (2) | BR112018011100A2 (OSRAM) |
| CA (2) | CA3007031A1 (OSRAM) |
| IL (1) | IL259713B1 (OSRAM) |
| MA (1) | MA43365A (OSRAM) |
| MX (1) | MX2018006333A (OSRAM) |
| SG (1) | SG11201803956UA (OSRAM) |
| UA (1) | UA126897C2 (OSRAM) |
| WO (2) | WO2017093447A1 (OSRAM) |
| ZA (1) | ZA201803079B (OSRAM) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3960855A1 (en) * | 2001-12-28 | 2022-03-02 | Chugai Seiyaku Kabushiki Kaisha | Method for stabilizing proteins |
| UA117901C2 (uk) | 2011-07-06 | 2018-10-25 | Ґенмаб Б.В. | Спосіб посилення ефекторної функції вихідного поліпептиду, його варіанти та їх застосування |
| CA3007031A1 (en) | 2015-12-01 | 2017-06-08 | Genmab B.V. | Anti-death receptor antibodies and methods of use thereof |
| TWI794171B (zh) | 2016-05-11 | 2023-03-01 | 美商滬亞生物國際有限公司 | Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療 |
| TWI808055B (zh) | 2016-05-11 | 2023-07-11 | 美商滬亞生物國際有限公司 | Hdac 抑制劑與 pd-1 抑制劑之組合治療 |
| CA3033665A1 (en) | 2016-08-12 | 2018-02-15 | Janssen Biotech, Inc. | Fc engineered anti-tnfr superfamily member antibodies having enhanced agonistic activity and methods of using them |
| EP3635005A1 (en) * | 2017-06-07 | 2020-04-15 | Genmab B.V. | Therapeutic antibodies based on mutated igg hexamers |
| MA50102A (fr) * | 2017-11-14 | 2020-07-15 | Univ Virginia Patent Foundation | Compositions et méthodes de fabrication et d'utilisation d'anticorps bispécifiques |
| CN109957020A (zh) * | 2017-12-25 | 2019-07-02 | 深圳宾德生物技术有限公司 | 一种靶向dr5的单链抗体、嵌合抗原受体t细胞及其制备方法和应用 |
| US20210107988A1 (en) * | 2018-01-24 | 2021-04-15 | Genmab B.V. | Polypeptide variants and uses thereof |
| BR112020022179A2 (pt) | 2018-05-03 | 2021-02-02 | Genmab B.V. | primeiro anticorpo, anticorpo, composição, métodos para tratar um indivíduo tendo uma doença, para esgotar uma população de célula e para induzir a proliferação em uma população de célula, e, kit. |
| MA53122A (fr) * | 2018-07-13 | 2021-05-19 | Genmab As | Variants d'anticorps cd38 et leurs utilisations |
| EP3837283B1 (en) * | 2018-08-16 | 2024-04-17 | Cantargia AB | Anti-il1rap antibody compositions |
| WO2020225456A1 (en) | 2019-05-09 | 2020-11-12 | Genmab B.V. | Dosage regimens for a combination of anti-dr5 antibodies for use in treating cancer |
| EP4055046A1 (en) | 2019-11-06 | 2022-09-14 | Genmab B.V. | Antibody variant combinations and uses thereof |
| KR20230010221A (ko) * | 2020-05-12 | 2023-01-18 | 아이쥐엠 바이오사이언스 인코포레이티드 | 암 치료를 위한 암 요법과 병용된 다량체 항-dr5 결합 분자의 용도 |
| CN111778333B (zh) * | 2020-07-03 | 2022-11-18 | 东莞市滨海湾中心医院 | 测定edar表达水平的试剂的应用和试剂盒 |
| WO2022018294A1 (en) | 2020-07-23 | 2022-01-27 | Genmab B.V. | A combination of anti-dr5 antibodies and an immunomodulatory imide drug for use in treating multiple myeloma |
| WO2022081869A1 (en) * | 2020-10-14 | 2022-04-21 | University Of Virginia Patent Foundation | Compositions and methods for overcoming dr5-induced immune evasion by solid tumors |
| CN112915211B (zh) * | 2021-02-07 | 2022-05-06 | 成都中医药大学 | 一种pd-l1靶向肽药物偶联物及其合成方法和应用 |
| EP4388013A4 (en) * | 2021-08-20 | 2025-12-24 | Univ Virginia Patent Foundation | A HIGHLY SUPERIOR DR5 ACTIVATION STRATEGY, PARTICULARLY IN TUMORS AND CANCERS |
| TW202509071A (zh) * | 2023-05-12 | 2025-03-01 | 丹麥商珍美寶股份有限公司 | 能夠與ｏｘ４０結合之抗體、其變異體及其用途 |
| GB202315963D0 (en) * | 2023-10-18 | 2023-11-29 | Cancer Research Tech Ltd | Binding molecules |
| WO2025160152A2 (en) * | 2024-01-23 | 2025-07-31 | The Regents Of The University Of California | Fas antibody and its use in treating cancers |
Family Cites Families (74)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6077A (en) | 1849-01-30 | Improved hinged claw-wrench | ||
| US835A (en) | 1838-07-12 | X i i i x | ||
| US761218A (en) | 1899-10-05 | 1904-05-31 | U S Standard Voting Machine Co | Register or counter. |
| US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
| US6284236B1 (en) | 1995-06-29 | 2001-09-04 | Immunex Corporation | Cytokine that induces apoptosis |
| KR970029803A (ko) | 1995-11-03 | 1997-06-26 | 김광호 | 반도체 메모리장치의 프리차지 회로 |
| CA2249206A1 (en) | 1996-04-01 | 1997-10-09 | Genentech, Inc. | Apo-2li and apo-3 apoptosis polypeptides |
| ES2284199T5 (es) | 1997-01-28 | 2011-11-14 | Human Genome Sciences, Inc. | Receptor 4 que contiene dominio de muerte (dr4: receptor 4 de muerte), miembro de la superfamilia de receptores de tnf y unión a trail (apo-2l). |
| US6872568B1 (en) | 1997-03-17 | 2005-03-29 | Human Genome Sciences, Inc. | Death domain containing receptor 5 antibodies |
| US20050233958A1 (en) | 1997-03-17 | 2005-10-20 | Human Genome Sciences, Inc. | Death domain containing receptor 5 |
| AU751659B2 (en) | 1997-05-02 | 2002-08-22 | Genentech Inc. | A method for making multispecific antibodies having heteromultimeric and common components |
| ES2316182T3 (es) | 1998-01-15 | 2009-04-01 | Genentech, Inc. | Ligando apo-2. |
| CA2329940A1 (en) | 1998-06-05 | 1999-12-09 | Mayo Foundation For Medical Education And Research | Use of genetically engineered antibodies to cd38 to treat multiple myeloma |
| US6355271B1 (en) | 1999-02-03 | 2002-03-12 | Biosante Pharmaceuticals, Inc. | Therapeutic calcium phosphate particles and methods of manufacture and use |
| US6281005B1 (en) | 1999-05-14 | 2001-08-28 | Copernicus Therapeutics, Inc. | Automated nucleic acid compaction device |
| WO2000075191A2 (en) | 1999-06-09 | 2000-12-14 | Genentech, Inc. | Apo-2L RECEPTOR AGONIST AND CPT-11 SYNERGISM |
| US6444640B1 (en) | 1999-09-30 | 2002-09-03 | Ludwig Institute For Cancer Research | Compositions of trail and DNA damaging drugs and uses thereof |
| TWI318983B (en) | 2000-05-02 | 2010-01-01 | Uab Research Foundation | An antibody selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and uses thereof |
| US7279160B2 (en) | 2000-05-02 | 2007-10-09 | The Uab Research Foundation | Combinations of DR5 antibodies and other therapeutic agents |
| DE10043437A1 (de) | 2000-09-04 | 2002-03-28 | Horst Lindhofer | Verwendung von trifunktionellen bispezifischen und trispezifischen Antikörpern zur Behandlung von malignem Aszites |
| US20020155109A1 (en) | 2001-04-20 | 2002-10-24 | Lynch David H. | Bispecific antibodies that bind TRAIL-R1 and TRAIL-R2 |
| US7115717B2 (en) | 2001-05-18 | 2006-10-03 | Kirin Beer Kabushiki Kaisha | Anti-TRAIL-R antibodies |
| US7361341B2 (en) | 2001-05-25 | 2008-04-22 | Human Genome Sciences, Inc. | Methods of treating cancer using antibodies that immunospecifically bind to trail receptors |
| ES2437992T3 (es) * | 2001-05-25 | 2014-01-15 | Human Genome Sciences, Inc. | Anticuerpos que se unen inmunoespecíficamente a los receptores de TRAIL |
| CA2451680C (en) | 2001-07-03 | 2011-04-19 | Genentech, Inc. | Human dr4 antibodies and uses thereof |
| IL161686A0 (en) | 2001-11-01 | 2004-09-27 | Uab Research Foundation | Combinations of antibodies selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and other therapeutic agents |
| US20040019915A1 (en) | 2002-04-01 | 2004-01-29 | Challita-Eid Pia M. | Nucleic acid and corresponding protein entitled 213P1F11 useful in treatment and detection of cancer |
| KR100932340B1 (ko) | 2002-10-17 | 2009-12-16 | 젠맵 에이/에스 | Ｃｄ20에 대한 인간 모노클로날 항체 |
| US20050266008A1 (en) | 2004-03-29 | 2005-12-01 | Medarex, Inc. | Human anti-IRTA-5 antibodies |
| KR20070010046A (ko) | 2004-04-06 | 2007-01-19 | 제넨테크, 인크. | Ｄｒ5 항체 및 그의 용도 |
| CN101001873B (zh) * | 2004-08-04 | 2013-03-13 | 曼璀克生物科技有限责任公司 | Fc区变体 |
| US7741568B2 (en) | 2005-01-13 | 2010-06-22 | The Wiremold Company | Downward facing receptacle assembly for cable raceway |
| EP3332808B1 (en) | 2005-03-03 | 2020-09-09 | Immunomedics Inc. | Humanized l243 antibodies |
| EP3050963B1 (en) | 2005-03-31 | 2019-09-18 | Chugai Seiyaku Kabushiki Kaisha | Process for production of polypeptide by regulation of assembly |
| PE20071101A1 (es) | 2005-08-31 | 2007-12-21 | Amgen Inc | Polipeptidos y anticuerpos |
| AU2007227292B2 (en) | 2006-03-17 | 2012-04-12 | Biogen Ma Inc. | Stabilized polypeptide compositions |
| CA2646965C (en) | 2006-03-24 | 2016-06-21 | Jonathan H. Davis | Engineered heterodimeric protein domains |
| KR100847010B1 (ko) | 2006-07-05 | 2008-07-17 | 아주대학교산학협력단 | 세포사멸 수용체 5 (ｄｒ5)에 특이적으로 결합하는 항체 및이를 포함하는 암 예방 또는 치료용 조성물 |
| AT503902B1 (de) | 2006-07-05 | 2008-06-15 | F Star Biotech Forsch & Entw | Verfahren zur manipulation von immunglobulinen |
| KR101799337B1 (ko) | 2007-06-21 | 2017-12-20 | 마크로제닉스, 인크. | 공유결합형 디아바디 및 이것의 사용 |
| TW200904072A (en) | 2007-07-05 | 2009-01-16 | Ic Plus Corp | System and method for generating interrupt |
| US20090162359A1 (en) | 2007-12-21 | 2009-06-25 | Christian Klein | Bivalent, bispecific antibodies |
| US8227577B2 (en) | 2007-12-21 | 2012-07-24 | Hoffman-La Roche Inc. | Bivalent, bispecific antibodies |
| US9266967B2 (en) | 2007-12-21 | 2016-02-23 | Hoffmann-La Roche, Inc. | Bivalent, bispecific antibodies |
| US8242247B2 (en) | 2007-12-21 | 2012-08-14 | Hoffmann-La Roche Inc. | Bivalent, bispecific antibodies |
| ES2563027T3 (es) | 2008-01-07 | 2016-03-10 | Amgen Inc. | Método para fabricación de moléculas heterodímeras Fc de anticuerpos utilizando efectos de conducción electrostática |
| EP2540740B1 (en) | 2008-06-17 | 2014-09-10 | Apogenix GmbH | Multimeric TNF receptors |
| EP2166021A1 (en) * | 2008-09-16 | 2010-03-24 | Ganymed Pharmaceuticals AG | Monoclonal antibodies for treatment of cancer |
| SG10201407908VA (en) | 2008-12-19 | 2015-01-29 | Macrogenics Inc | Covalent diabodies and uses thereof |
| EP2424567B1 (en) | 2009-04-27 | 2018-11-21 | OncoMed Pharmaceuticals, Inc. | Method for making heteromultimeric molecules |
| US20120070432A1 (en) | 2009-05-28 | 2012-03-22 | Amgen Inc. | Treatment of pancreatic cancer using a dr5 agonist in combination with gemcitabine |
| MX368932B (es) | 2009-06-26 | 2019-10-22 | Regeneron Pharma | Anticuerpos biespecificos facilmente aislados con formato de inmunoglobulina original. |
| US9493578B2 (en) | 2009-09-02 | 2016-11-15 | Xencor, Inc. | Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens |
| US9150663B2 (en) | 2010-04-20 | 2015-10-06 | Genmab A/S | Heterodimeric antibody Fc-containing proteins and methods for production thereof |
| WO2011143545A1 (en) | 2010-05-14 | 2011-11-17 | Rinat Neuroscience Corporation | Heterodimeric proteins and methods for producing and purifying them |
| JP5997154B2 (ja) | 2010-08-16 | 2016-09-28 | ノビミューン エスアー | 多重特異性多価抗体の生成方法 |
| WO2012025530A1 (en) | 2010-08-24 | 2012-03-01 | F. Hoffmann-La Roche Ag | Bispecific antibodies comprising a disulfide stabilized - fv fragment |
| RU2013110876A (ru) | 2010-08-24 | 2014-09-27 | Рош Гликарт Аг | Активируемые биспецифические антитела |
| EP2725034B1 (en) | 2010-09-22 | 2019-04-03 | Amgen Inc. | Carrier immunoglobulins with no specificity for human tissues and uses thereof |
| RU2644678C1 (ru) * | 2010-10-29 | 2018-02-13 | Дайити Санкио Компани, Лимитед | Новое антитело против dr5 |
| RU2604490C2 (ru) | 2010-11-05 | 2016-12-10 | Займворкс Инк. | ДИЗАЙН УСТОЙЧИВОГО ГЕТЕРОДИМЕРНОГО АНТИТЕЛА С МУТАЦИЯМИ В Fc ДОМЕНЕ |
| CN102250246A (zh) | 2011-06-10 | 2011-11-23 | 常州亚当生物技术有限公司 | 抗VEGF/PDGFRβ双特异性抗体及其应用 |
| UA117901C2 (uk) | 2011-07-06 | 2018-10-25 | Ґенмаб Б.В. | Спосіб посилення ефекторної функції вихідного поліпептиду, його варіанти та їх застосування |
| CN102654260B (zh) | 2011-09-29 | 2014-09-03 | 北京京东方光电科技有限公司 | 一种背光源和液晶显示器 |
| PL2794905T3 (pl) | 2011-12-20 | 2020-11-02 | Medimmune, Llc | Zmodyfikowane polipeptydy dla rusztowań przeciwciał dwuswoistych |
| CN120383672A (zh) | 2012-04-20 | 2025-07-29 | 美勒斯公司 | 用于产生免疫球蛋白样分子的方法和手段 |
| DK2869845T3 (da) | 2012-07-06 | 2019-12-09 | Genmab Bv | Dimert protein med tredobbelte mutationer |
| JP6514103B2 (ja) | 2012-07-06 | 2019-05-15 | ゲンマブ ビー．ブイ． | 三重変異を有する二量体タンパク質 |
| EP2684896A1 (en) * | 2012-07-09 | 2014-01-15 | International-Drug-Development-Biotech | Anti-DR5 family antibodies, bispecific or multivalent anti-DR5 family antibodies and methods of use thereof |
| KR20220156667A (ko) | 2013-01-10 | 2022-11-25 | 젠맵 비. 브이 | 인간 IgG1 Fc 영역 변이체 및 그의 용도 |
| EP3048116A1 (en) * | 2015-01-23 | 2016-07-27 | International-Drug-Development-Biotech | Anti-dr5 antibodies with enhanced apoptosis potency |
| CA3007031A1 (en) | 2015-12-01 | 2017-06-08 | Genmab B.V. | Anti-death receptor antibodies and methods of use thereof |
| EP3535291A1 (en) | 2016-11-01 | 2019-09-11 | Genmab B.V. | Polypeptide variants and uses thereof |
| JP7577446B2 (ja) | 2017-02-10 | 2024-11-05 | ジェンマブ ビー．ブイ． | ポリペプチドバリアントおよびそれらの使用 |
-
2016
- 2016-12-01 CA CA3007031A patent/CA3007031A1/en active Pending
- 2016-12-01 BR BR112018011100-7A patent/BR112018011100A2/en active Search and Examination
- 2016-12-01 JP JP2018529176A patent/JP2019501151A/ja not_active Withdrawn
- 2016-12-01 WO PCT/EP2016/079517 patent/WO2017093447A1/en not_active Ceased
- 2016-12-01 CA CA3007033A patent/CA3007033A1/en active Pending
- 2016-12-01 US US15/780,268 patent/US20190144554A1/en not_active Abandoned
- 2016-12-01 SG SG11201803956UA patent/SG11201803956UA/en unknown
- 2016-12-01 US US15/780,285 patent/US20190202926A1/en not_active Abandoned
- 2016-12-01 CN CN201680080715.XA patent/CN109476737A/zh active Pending
- 2016-12-01 CN CN201680069617.6A patent/CN108884158A/zh active Pending
- 2016-12-01 UA UAA201807311A patent/UA126897C2/uk unknown
- 2016-12-01 AU AU2016363770A patent/AU2016363770A1/en not_active Abandoned
- 2016-12-01 BR BR112018011058-2A patent/BR112018011058A2/en active Search and Examination
- 2016-12-01 MX MX2018006333A patent/MX2018006333A/es unknown
- 2016-12-01 MA MA043365A patent/MA43365A/fr unknown
- 2016-12-01 EP EP16805417.9A patent/EP3383906A1/en not_active Withdrawn
- 2016-12-01 EP EP24170877.5A patent/EP4464333A3/en active Pending
- 2016-12-01 EP EP24172544.9A patent/EP4467648A3/en active Pending
- 2016-12-01 KR KR1020187018606A patent/KR20180098567A/ko not_active Ceased
- 2016-12-01 WO PCT/EP2016/079518 patent/WO2017093448A1/en not_active Ceased
- 2016-12-01 JP JP2018529087A patent/JP7254515B2/ja active Active
- 2016-12-01 EP EP16805416.1A patent/EP3383905A1/en not_active Withdrawn
-
2018
- 2018-05-10 ZA ZA2018/03079A patent/ZA201803079B/en unknown
- 2018-05-30 IL IL259713A patent/IL259713B1/en unknown
-
2019
- 2019-06-25 US US16/451,714 patent/US10882913B2/en active Active
-
2020
- 2020-12-01 US US17/108,373 patent/US12247080B2/en active Active
-
2022
- 2022-03-01 US US17/684,238 patent/US20220411522A1/en active Pending
- 2022-11-28 JP JP2022188988A patent/JP7679347B2/ja active Active
-
2024
- 2024-01-15 AU AU2024200261A patent/AU2024200261A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019500869A5 (OSRAM) | ||
| JP2019501151A5 (OSRAM) | ||
| US11103579B2 (en) | Combination of DR5 agonist and anti-PD-1 antagonist and methods of use | |
| RU2017118225A (ru) | Антитела к PD-1 и способы их применения | |
| JP2020502046A5 (OSRAM) | ||
| JP2021501162A5 (OSRAM) | ||
| JP2020522543A5 (OSRAM) | ||
| RU2019138337A (ru) | Конъюгаты на основе антитела, содержащие агонист toll-подобного рецептора, и виды комбинированной терапии | |
| HRP20230517T1 (hr) | Kombinacija anti-pd-1 antitijela i radijacijske terapije za liječenje raka | |
| JP2020501531A5 (OSRAM) | ||
| JP2019519499A5 (OSRAM) | ||
| JP2018516969A5 (OSRAM) | ||
| JP2017514795A5 (OSRAM) | ||
| JP2018503365A5 (OSRAM) | ||
| JP2009521496A5 (OSRAM) | ||
| JP2019506403A5 (OSRAM) | ||
| JP2014522850A5 (OSRAM) | ||
| JP2017535257A5 (OSRAM) | ||
| JP2008540447A5 (OSRAM) | ||
| JP2017500057A5 (OSRAM) | ||
| JPWO2021194942A5 (OSRAM) | ||
| JP2016503067A5 (OSRAM) | ||
| JP2020527332A5 (OSRAM) | ||
| US20190262354A1 (en) | Combinations of pbd-based antibody drug conjugates with flt3 inhibitors | |
| JP2020515577A5 (OSRAM) |